What is NodThera?
NodThera is a pioneering biotechnology company dedicated to addressing the root causes of chronic inflammatory diseases. By focusing on the NLRP3 inflammasome pathway, NodThera aims to develop groundbreaking medicines that can offer new therapeutic avenues for a wide range of debilitating conditions. The company's scientific foundation is built on extensive research into inflammation's role in chronic disease, positioning NodThera at the forefront of innovation in this critical area of healthcare. Their experienced team is committed to translating scientific discoveries into impactful treatments for patients worldwide.
How much funding has NodThera raised?
NodThera has raised a total of $95M across 2 funding rounds:
Series A
$40M
Series B
$55M
Series A (2018): $40M with participation from Epidarex Capital, Sofinnova Partners, F-Prime Capital, and 5AM Ventures
Series B (2020): $55M led by F-Prime Capital, Novo Ventures, Cowen Healthcare Investments, 5AM Ventures, Epidarex Capital, Sofinnova Partners, and Sanofi Ventures
Key Investors in NodThera
F-Prime Capital
F-Prime Capital is a venture capital firm established in 2002, focusing on investments in healthcare and technology. They provide a team of investors, engineers, doctors, and scientists to support portfolio companies.
Novo Ventures
Novo Holdings, established in 1999 and headquartered in Denmark, is a private limited liability company wholly owned by the Novo Nordisk Foundation, investing in healthcare and biotechnology.
Cowen Healthcare Investments
Cowen, founded in 1918 and based in New York City, is an independent financial services firm offering investment banking, research, and investment management, with a focus on healthcare.
What's next for NodThera?
The recent major strategic investment signals a strong vote of confidence in NodThera's scientific approach and therapeutic pipeline. This capital infusion is expected to accelerate the company's research and development efforts, potentially advancing its lead candidates through clinical trials and towards commercialization. NodThera's focus on NLRP3 inflammasome inhibition places it in a unique position to address unmet medical needs in chronic inflammatory diseases, suggesting a trajectory towards significant growth and market impact. The company's continued progress will be closely watched by the biotech and investment communities.
See full NodThera company page
